Ipamorelin vs Tesamorelin: Head-to-Head Comparison
Ipamorelin (ghrelin pathway) and tesamorelin (GHRH pathway) stimulate GH through different mechanisms. Tesamorelin is FDA-approved for HIV lipodystrophy with proven visceral fat reduction, while ipamorelin offers the cleanest side-effect profile of any GHRP but lacks FDA approval.
Side-by-Side Comparison
| Dimension | Ipamorelin | Tesamorelin |
|---|---|---|
| Evidence Level | Phase II trials | Phase III trials, FDA-approved |
| FDA Status | Not approved | FDA-approved (Egrifta) |
| Mechanism | Ghrelin receptor agonist | GHRH analog |
| Primary Use | GH optimization, body composition, anti-aging | Visceral fat reduction (HIV lipodystrophy) |
| Side Effects | Minimal; no cortisol/prolactin impact | Arthralgia, injection site reactions, edema |
| Cost | Moderate (research peptide) | Very high (branded pharmaceutical) |
| Fat Reduction Evidence | Indirect via GH elevation | Direct clinical evidence for visceral fat reduction |
Peptide Overviews
Ipamorelin
BHuman StudiesIpamorelin is a selective growth hormone secretagogue that stimulates growth hormone release from the pituitary gland without significantly affecting cortisol or prolactin levels.
Tesamorelin
AFDA ApprovedTesamorelin is a synthetic GHRH analog approved by the FDA as Egrifta for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
Ipamorelin vs Tesamorelin: FAQ
Stay Informed on Peptide Research
Get weekly comparison updates, new study alerts, and regulatory changes.
No spam. Unsubscribe anytime.
Medical Disclaimer
This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.
Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Do not disregard professional medical advice based on information found on this site.
No claims of therapeutic efficacy are made for substances that are not FDA-approved for the discussed indications. Research citations reflect published findings and do not imply endorsement.